Company Overview
- Website
- arbutusbio.com
- Phone
- (267) 469-0914
- Employees
- 85
- Founded in
- 1992
- Industry
- BioTech/Drugs
- Stock Symbol
- NASDAQ:ABU
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services5417 - Scientific Research and Development Services54171 - Research and Development in the Physical, Engineering, and Life Sciences541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- SIC Codes
-
87 - Engineering, Accounting, Research, Management, and Related Services873 - Research, Development, and Testing Services
Financials & Stats
Revenue
$22B
Total Funding Amount
$116M
Recent News & Media
Arbutus Biopharma Reacquires China Rights to Imdusiran, Forms Scientific Advisory Board
- Jul 8, 2025
- msn.com
Arbutus Biopharma (NASDAQ:ABUS) Trading Down 2.8% - What's Next?
- Jun 29, 2025
- marketbeat.com
Arbutus Biopharma Reacquires Rights to Imdusiran in Greater China, Concludes Partnership with Qilu Pharmaceutical
- Jun 25, 2025
- nasdaq.com
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
- Jun 25, 2025
- tipranks.com
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
- May 14, 2025
- globenewswire.com
Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
- Apr 23, 2025
- tipranks.com
Who is Arbutus Biopharma Corporation
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania. The company employs 85 people and generates approximately $21.5 million in annual revenue. Arbutus Biopharma focuses on developing novel therapeutics for patients with chronic hepatitis B virus (cHBV). Their approach centers on suppressing HBV DNA, reducing surface antigen, and boosting the body's immune response to the virus. The company's pipeline includes two proprietary compounds: imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. Imdusiran has demonstrated clinical efficacy in reducing surface antigen and reawakening the immune response to HBV. Currently, it is being evaluated in three Phase 2a combination clinical trials. AB-101 is in a Phase 1a/1b clinical trial. For more information, visit Arbutus Biopharma's website at arbutusbio.com.